OptInsights

Launching in Europe
Launching in Europe with synchronized omnichannel consentBlogConsent collectionEU GDPRHCPOmnichannel

Launching in Europe with synchronized omnichannel consent

Martijn van den CorputMartijn van den CorputOctober 10, 2026
Optinsight Hidden Consent
Hidden opt-ins and opt-outs sitting in your CRM nowBlogCRMHCPData quality

Hidden opt-ins and opt-outs sitting in your CRM now

Michel van KoningsbruggeMichel van KoningsbruggeOctober 9, 2026
GDPR for Pharma
GDPR for pharma: A practical framework for HCP dataHCPEU GDPRBlog

GDPR for pharma: A practical framework for HCP data

Martijn van den CorputMartijn van den CorputOctober 6, 2026
Mapping HCP journey
Mapping the HCP journey: Where permission fits bestBlogHCPConsent collection

Mapping the HCP journey: Where permission fits best

Martijn van den CorputMartijn van den CorputOctober 5, 2026
GDPR for Biotech
GDPR for biotech: Engaging HCPs with consent in EuropeEU GDPRBlog

GDPR for biotech: Engaging HCPs with consent in Europe

Martijn van den CorputMartijn van den CorputOctober 2, 2026
optinsight consent management solution software contact
Product update what’s new in the OptInsight Consent & Preference platformBlog

Product update what’s new in the OptInsight Consent & Preference platform

Martijn van den CorputMartijn van den CorputSeptember 29, 2026
Omnichannel engagement
Brand impact of not processing HCP data according to consentBlog

Brand impact of not processing HCP data according to consent

Martijn van den CorputMartijn van den CorputMay 19, 2026
Omnichannel engagement
Omnichannel engagement: Will you scale risk or impact?Blog

Omnichannel engagement: Will you scale risk or impact?

Martijn van den CorputMartijn van den CorputJanuary 14, 2026
OptInsights 44: The overlooked link between communication preferences and HCP consentBlog

OptInsights 44: The overlooked link between communication preferences and HCP consent

Martijn van den CorputMartijn van den CorputSeptember 26, 2025
Pharma and biotechs are burning money as a result of poor data quality
OptInsights 43: Pharma and biotechs are burning money as a result of poor data quality.Blog

OptInsights 43: Pharma and biotechs are burning money as a result of poor data quality.

Martijn van den CorputMartijn van den CorputSeptember 4, 2025
navigating digital consent in europe
OptInsights 42: US-based Pharma Companies and Biotechs that want to enter European marketConsent & preference management solutionBlog

OptInsights 42: US-based Pharma Companies and Biotechs that want to enter European market

Martijn van den CorputMartijn van den CorputJune 11, 2025
Consent management in Europe between physicians and pharmaceutical companies
OptInsights 41: Consent management in Europe between physicians and pharmaceutical companiesConsent & preference management solutionBlog

OptInsights 41: Consent management in Europe between physicians and pharmaceutical companies

Martijn van den CorputMartijn van den CorputMay 19, 2025
HCP data protection
OptInsights 40: HCP Data protectionBlog

OptInsights 40: HCP Data protection

Martijn van den CorputMartijn van den CorputMay 9, 2025
effective communication HCP
OptInsights 39: Why effective digital communication with HCPs still failsBlog

OptInsights 39: Why effective digital communication with HCPs still fails

Martijn van den CorputMartijn van den CorputApril 14, 2025
How to cope with opt outs OptInsight
OptInsights 38: How to cope with opt-outs?Blog

OptInsights 38: How to cope with opt-outs?

Martijn van den CorputMartijn van den CorputApril 4, 2025
Collecting personal data where the HCP resides
OptInsights 37:
Collecting personal data where the HCP residesConsent & preference management solutionBlog

OptInsights 37:
Collecting personal data where the HCP resides

Martijn van den CorputMartijn van den CorputMarch 6, 2025